When was ONCOtracker founded?

ONCOtracker was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is ONCOtracker located?

ONCOtracker is headquartered in West Hollywood, United States.

Who is the current CEO of ONCOtracker?

James R Berenson of ONCOtracker. They have also founded 1 company.

How many employees does ONCOtracker have?

As of Aug 31, 2026, the latest employee count at ONCOtracker is 5.

Is ONCOtracker a funded company?

ONCOtracker is a funded company, having raised a total of $1.3M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 10, 2016.

When was the latest funding round of ONCOtracker?

ONCOtracker's latest funding was a $***** Seed round on Feb 13, 2020, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.31B in funding in 2026 to date.

Where does ONCOtracker rank among its competitors?

ONCOtracker ranks 210th amongst 534 active competitors, of which 136 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Alamar Biosciences, which secured $50M in Jan, 2026.

Who are the top competitors of ONCOtracker?

ONCOtracker's top competitors include Natera, Guardant Health and Foundation Medicine. Among them, Alamar Biosciences secured the most recent funding round in January, 2026.

ONCOtracker - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of immune assays for the diagnosis of cancer. The company's diagnostic assay is used for testing multiple myeloma, B-cell malignancies and other related disorders. It includes Serum B-Cell Maturation Antigen (sBCMA) blood test assay, which is used to monitor the tumour and predict the therapeutic outcome of patients with multiple myeloma. It is used to treat chronic lymphocytic leukaemia, B-cell lymphoma and solid tumour.

Website: oncotracker.com
Social
Email ID: *****@oncotracker.com
Phone Number: +1 **********

Key Metrics

Founded Year

2014

Location

West Hollywood, United States

Stage

Seed

Total Funding

$1.3M in 3 rounds

Latest Funding Round

Seed, Feb 13, 2020, $*****

Ranked

210^th among 534 active competitors

Employee Count

5 as on Aug 31, 2026

Similar Companies

Natera & 622 more

View ONCOtracker's full profile

ONCOtracker has raised a total funding of $1.3M over 3 rounds. Its first funding round was on Nov 10, 2016.

Here is the list of recent funding rounds of ONCOtracker:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2020	4478541	Seed	6458440	2981675	9023601	2230078
Mar 13, 2019	8155223	Seed	2795682	4288790	7564427	6242677
Nov 10, 2016	3345587	Seed	3933527	4650334	2736743	5089006

Access funding benchmarks and valuations. Sign up today!

View details of ONCOtracker's funding rounds and investors

The founders of ONCOtracker is James R Berenson. James R Berenson is the CEO of ONCOtracker.

Here are the details of ONCOtracker's key team members:

James R Berenson: Founder & CEO of ONCOtracker.

View details of ONCOtracker's Founder profiles and Board Members

ONCOtracker's employee count trend

ONCOtracker has 5 employees as of Aug 26. Here is ONCOtracker's employee count trend over the years:

Uncover ONCOtracker's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ONCOtracker include Natera, Guardant Health and Foundation Medicine. Here is the list of Top 10 competitors of ONCOtracker, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	80/100
2nd	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	SoftBank Vision Fund, Lightspeed Venture Partners ... & 25 others	79/100
3rd	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Redmile Group, Deerfield & 11 others	70/100
4th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
5th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
6th	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	68/100
7th	Crown Bioscience 2006, Santa Clara (United States), Acquired	Developer of drugs for cancer and CVMD (Cardiovascular and Metabolic Diseases)	$85.9M	The CID Group, Orbimed & 16 others	68/100
8th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
9th	Alamar Biosciences 2018, Fremont (United States), Public	Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels	$250M	Sands Capital, Sherpa Healthcare Partners ... & 7 others	66/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
210th	ONCOtracker 2014, West Hollywood (United States), Seed	Developer of immune assays for the diagnosis of cancer	$1.3M	-	31/100